Sermorelin Acetate – 10 Vials (CAS: 86168-78-7)

Price range: $327.00 through $382.00

Sermorelin Acetate is a synthetic 29-amino acid peptide corresponding to the amino-terminal segment of human growth hormone-releasing hormone (GHRH). This high-purity lyophilized powder is widely researched for its ability to stimulate endogenous growth hormone secretion through GHRH receptor activation, making it a valuable tool for investigating the GH/IGF-1 axis. Supplied for laboratory research use only.

Description

Sermorelin Acetate (also known as GHRH(1-29)NH₂, GRF(1-29), or Geref) is a synthetic peptide identical to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH) . It represents the shortest fragment of GHRH that retains full biological activity, containing the complete receptor-binding and activation domains of the native hormone .

This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.

 

Key Research Focus

Sermorelin Acetate has been investigated in preclinical and clinical research exploring its roles in:

  • GHRH Receptor Agonism and GH Secretion: Sermorelin directly stimulates the pituitary gland by binding to the GHRH receptor (GHRHR), triggering the release of endogenous growth hormone in a pulsatile, physiologically regulated pattern . Unlike exogenous growth hormone, sermorelin preserves the hypothalamic-pituitary feedback loop, allowing somatostatin to modulate GH output when levels are adequate .
  • Diagnostic Use for Growth Hormone Deficiency: Sermorelin was historically FDA-approved as a diagnostic agent to assess pituitary GH secretory capacity in patients with suspected growth hormone deficiency . Intravenous administration produces a rapid and relatively specific GH response, with a diagnostic threshold of peak GH <10 µg/L used to confirm GHD in children .
  • Pharmacokinetics and Short Half-Life: Sermorelin has a short disappearance half-life of approximately 4.3 ± 1.4 minutes following intravenous or subcutaneous administration . This rapid clearance underlies its pulsatile stimulation profile, which contrasts with longer-acting GHRH analogs like CJC-1295.

 

Regulatory Status

Sermorelin Acetate was approved by the FDA in 1997 for the diagnosis and treatment of idiopathic growth hormone deficiency in children . The manufacturer voluntarily discontinued the product in 2008 for commercial reasons, not safety or efficacy concerns . Sermorelin is currently listed on the FDA’s Category 1 bulk drug substances list, permitting compounding under Section 503A with a patient-specific prescription . No FDA-approved sermorelin product currently exists on the market.

 

Safety Considerations (Clinical Context)

  • Common Adverse Effects: Injection-site reactions (pain, redness, swelling), transient facial flushing, headache, nausea, and dizziness .
  • Serious Risks (Theoretical): GH/IGF-1 signaling has mitogenic potential; no established clinical carcinogenic signal exists, but long-term safety data are unavailable .
  • Athlete Status: Sermorelin is a prohibited substance on the WADA Prohibited List and is banned for use in competition .

 

Product Specifications

  • Form: Lyophilized Powder (Sterile)
  • Purity: ≥95–98% (HPLC Verified)
  • Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S (free base)
  • Molecular Weight: ~3357.9 Da (free base)
  • CAS Number: 114466-38-5 (acetate salt)
  • Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
  • Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
  • Solubility: Soluble in water or sterile buffer for laboratory use.
  • Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.

 

Why Choose Sermorelin Acetate?

Sermorelin Acetate offers a research tool for studying GHRH receptor activation and endogenous GH secretion with a well-characterized, physiologically regulated mechanism. Its short half-life and pulsatile stimulation profile contrast with longer-acting analogs (CJC-1295 with DAC) and exogenous GH, making it suitable for protocols examining physiological GH pulse architecture and feedback regulation . The historical FDA approval and extensive diagnostic use provide a translational foundation for experimental design. Researchers should note that the original product was discontinued in 2008, and current research-grade material is not FDA-approved for any indication.

Additional information

Grams

5mg, 10mg

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.